Welcoming Liping Meng as President-Elect of CABS for 2026！

Dear CABS Members, Partners, and Friends,

It is with great pleasure that the Chinese American Biopharmaceutical Society (CABS) announce Liping Meng, PhD, Principal Scientist II at Gilead Sciences, as our President-Elect for 2026. With over 15 years of leadership experience in drug development and a longstanding commitment to CABS, Liping is well-prepared to guide the organization toward continued growth and innovation.

Dr. Meng is a recognized scientific and CMC leader with a proven record of advancing therapeutics from preclinical development to commercialization. With a strong foundation in organic chemistry and broad expertise across analytical development, regulatory strategy, and quality control, she has successfully led more than 20 drug programs across all phases of development. Notably, she played a pivotal role in the regulatory journey of Sunlenca® (lenacapavir), leading to FDA approval as a groundbreaking, twice-yearly treatment for individuals with multidrug-resistant HIV. Before joining Gilead in 2015, Liping held a leadership position at AnaSpec. Prior to that, she conducted research at UC Davis after completing her doctoral degree in Organic Chemistry from the University of Tuebingen, Germany.

Beyond her professional accomplishments, Liping has demonstrated exceptional leadership within CABS. Over the past decade, she has contributed significantly to the organization, serving as Co-Chair of the Membership Committee (2012–2017), Co-Chair of Business and Career Development Committee (2017-2023), and Co-Chair of Science and Technology Committee (2023–present).  Her outstanding contributions have been recognized with numerous accolades, including:

● 2014: CABS President’s Outstanding Service Award

● 2015: Outstanding Leadership and Service Award

● 2018: Distinguished Leadership and Contribution to CABS

● 2022: Ten Years of Extraordinary Leadership

● 2023: “Always There” Adamant Dedication Recognition

● 2024: Outstanding Co-Chair Award

● 2025: The USA President’s Volunteer Service Award

Liping’s dedication to CABS and her remarkable professional journey make her an ideal leader for the next chapter of our organization. Her vision and expertise will ensure CABS continues to thrive as a hub for scientific excellence and global collaboration.

With the election completed, Liping will now serve as the 2025-2026 President-Elect alongside Sihong Zhou, who will be the 2025-2026 President of CABS. Please join me in congratulating both Liping and Sihong on their new roles. We eagerly anticipate a dynamic tenure under their leadership and the continued growth of CABS through the collective efforts of our talented members and volunteers.

Thank you for your continued support and dedication to CABS!

Sincerely,

Kay Tong,

2024-2025 President of Chinese American Biopharmaceutical Society (CABS)




.